Christos Sotiriou, MD, PhD, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium., highlights the findings of two studies conducted into the importance of biomarkers in assessing treatment efficacy in patients with breast cancer. The first study focused on evaluating the abundance and diversity of B- and T-cell receptors in the tumor microenvironment and finding how that correlates with the response to immunotherapy. The second study looked at tumor DNA levels in plasma throughout treatment and how those might be associated with patient responses. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
